NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies
Eli Lilly and Company
Summary
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy: * Diffuse large B-cell lymphoma - not otherwise specified * High-grade B-cell lymphoma * Follicular large B-cell lymphoma * Follicular lymphoma * Other non-Hodgkin lymphoma * Has measurable disease * Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy Exclusion Criteria: * Has an active second cancer * Has known or suspected history of central nervous system…
Interventions
- DrugLY4584180
administered orally
- DrugRituximab
administered through IV infusion
Locations (45)
- Mayo Clinic - ScottsdaleScottsdale, Arizona
- City of HopeDuarte, California
- University of California, Los Angeles (UCLA) - Medical CenterLos Angeles, California
- University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer CenterSan Francisco, California
- Colorado Blood Cancer InstituteDenver, Colorado
- University of Miami - Sylvester Cancer CenterMiami, Florida